✦ LIBER ✦

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study

✍ Scribed by Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balcerzak; Liboria Militello

Publisher: Springer US
Year: 1988
Tongue: English
Weight: 240 KB
Volume: 6
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00175403

No coin nor oath required. For personal study only.

✦ Synopsis

Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2-21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued.

📜 SIMILAR VOLUMES

A phase II evaluation of ifosfamide and

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A southwest oncology group study

✍ Bernard L. Zidar; Barbara Metch; Stanley P. Balcerzak; H. Irving Pierce; Liboria 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB

A phase II evaluation of tamoxifen in un

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study

✍ J. Wendall Goodwin; John Crowley; Harmon J. Eyre; Benjamin Stafford; Kurt A. Jae 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 252 KB

Phase II trial of five day intravenous i

Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study

✍ John D. Cowan; Stephanie Green; Joel Lucas; James K. Weick; Stanley P. Balcerzak 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 116 KB

Phase II evaluation of bleomycin. A Sout

Phase II evaluation of bleomycin. A Southwest Oncology Group study

✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

A phase II study of VP-16 and cisplatin

A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma

✍ Elizabeth A. Eisenhauer; William K. Evans; Nevin Murray; Walter Kocha; Rafal Wie 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 204 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of VP-16 100 mg/m 2 daily x 3 and cisplatin 25 mg/m 2 daily x 3 in untreated patients with malignant mesothelioma. Twenty-seven eligible patients were entered on the trial and the majority had pleur

Phase II study of cisplatin in recurrent

Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study

✍ David J. Stewart; Robert M. O'Bryan; Muhyi Al-Sarraf; John J. Costanzi; Noboru O 📂 Article 📅 1983 🏛 Springer US 🌐 English ⚖ 215 KB

Thirty-one evaluable adults with recurrent astrocytomas were treated with Cisplatin 35 mg/m 2 I.V. daily for three days every 3 4 weeks. All patients had previously been irradiated and most had previously received chemotherapy. Approximately half had poor performance status. Two patients experienced